Multiple sclerosis can be inhibited or reversed using a novel gene therapy technique that stops the disease’s immune response in mouse models, University of Florida Health researchers have found.
By combining a brain-protein gene and an existing medication, the researchers were able to prevent the mouse version of multiple sclerosis. Likewise, the treatments produced near-complete remission in the animal models. The findings, which researchers said have significant potential for treating multiple sclerosis and other autoimmune disorders, are published today (Sept. 21) in the journal Molecular Therapy.
Multiple sclerosis affects about 2.3 million people worldwide and is the most common neurological disease in young adults. The incurable disorder starts when the immune system attacks the myelin sheath surrounding nerve fibers, making them misfire and leading to problems with muscle weakness, vision, speech and muscle coordination.
The researchers used a harmless virus, known as an adeno-associated virus, to deliver a gene responsible for a brain protein into the livers of the mouse models. The virus sparked production of so-called regulatory T cells, which suppress the immune system attack that defines multiple sclerosis. The gene was targeted to the liver because it has the ability to induce immune tolerance.
“Using a clinically tested gene therapy platform, we are able to induce very specific regulatory cells that target the self-reactive cells that are responsible for causing multiple sclerosis,” said Brad E. Hoffman, Ph.D., an assistant professor in the departments of pediatrics and neuroscience at the University of Florida College of Medicine.
The protein, myelin oligodendrocyte glycoprotein, was found to be effective in preventing and reversing muscular dystrophy on its own. A group of five mouse models that received the gene therapy did not develop experimental autoimmune encephalomyelitis, which is the mouse equivalent of multiple sclerosis in humans. In another experiment, all but one mouse model showed a significant reversal of the disease eight days after a single gene therapy treatment.
Hoffman said he was also encouraged by the treatment’s longevity. After seven months, the mouse models that were treated with gene therapy showed no signs of disease, compared with a group of untreated mouse models that had neurological problems after 14 days.
When the protein was combined with rapamycin — a drug used to coat heart stents and prevent organ transplant rejection — its effectiveness was further improved, the researchers found. The drug was chosen because it allows helpful regulatory T-cells to proliferate while blocking undesirable effector T-cells, Hoffman said.
Among the mouse models that were given rapamycin and the gene therapy, 71 percent and 80 percent went into near-complete remission after having hind-limb paralysis. That, Hoffman said, shows the combination can be especially effective at stopping rapidly progressing paralysis.
While researchers have established how gene therapy stimulates regulatory T cells in the liver, Hoffman said little else is known about the detailed mechanics of how that process works.
Before the therapy can be tested in humans during a clinical trial, further research involving other preclinical models will be needed, Hoffman said. Researchers also need to target the full suite of proteins that are implicated in multiple sclerosis, he added.
Still, Hoffman said he is extremely optimistic that the gene therapy can be effective in humans.
“If we can provide long-term remission for people and a long-term quality of life, that is a very promising outcome,” he said.
The Latest on: Multiple Sclerosis
- Russian Engineers Create a New MRI Scanner for Overweight Peopleon November 30, 2019 at 4:32 am
Magnetic resonance imaging is one of the most effective diagnostic methods in modern medicine. With the help of a magnetic resonance imaging scanner, cancer, multiple sclerosis, diseases of the ...
- Treatment for multiple sclerosis shows promising signson November 30, 2019 at 12:24 am
Most people know "someone" with multiple sclerosis, with around 10 Australians diagnosed with the autoimmune disease each week. While MS conjures up images of wheelchair bound "sufferers" the reality ...
- Biogen will offer discounts to a health plan if patients say its multiple sclerosis drugs don’t workon November 27, 2019 at 9:06 am
In a twist on value-based contracting, a drug maker has agreed to offer a larger discount that a commercial health plan will receive for medicines – but only based on outcomes that patients report. In ...
- Investigators narrow in on a microRNA for treating multiple sclerosison November 26, 2019 at 8:03 am
It turns out the gut is full of surprises. And one of those surprises may have offered up a key for unlocking a new way of treating multiple sclerosis (MS). Investigators from Brigham and Women's ...
- New method to separate two variants of common herpes virus linked to multiple sclerosison November 26, 2019 at 7:40 am
Researchers at Karolinska Institutet have developed a new method to separate between two different types of a common herpes virus (HHV-6) that has been linked to multiple sclerosis. By analyzing ...
- Ministry of health and prevention launches "Ea'nah" initiative to support patients with multiple sclerosis, atopic dermatitis and severe asthmaon November 26, 2019 at 3:59 am
Currently, there is a number of multiple sclerosis, atopic dermatitis, and severe asthma patients in the UAE who face cost as a barrier to completing or adhering to their treatment. Together with the ...
- Multiple sclerosis linked to variant of common herpes virus through new methodon November 26, 2019 at 3:57 am
Researchers at Karolinska Institutet have developed a new method to separate between two types of a common herpes virus (HHV-6) that has been linked to multiple sclerosis (MS). By analyzing antibodies ...
- Pharma execs tell researchers that multiple sclerosis drug pricing is based on competition, not R&D costson November 25, 2019 at 1:05 pm
Despite claims that prices for new medicines are generally shaped by R&D costs, initial pricing decisions in the U.S. for multiple sclerosis drugs have been driven by other factors, especially what ...
- Multiple Sclerosis Management Challenges and Opportunities: A Q&A With Thomas Leist, MD, PhDon November 25, 2019 at 12:59 pm
Thomas Leist, MD, PhD, Director of the Comprehensive Multiple Sclerosis Center and Professor of Neuroloy at Thomas Jefferson University Hospital, discusses the changing MS therapeutic landscape, the ...
- Study shows the progression of multiple sclerosis can be slowedon November 25, 2019 at 12:07 am
Multiple sclerosis (MS) is difficult to diagnose, and, as yet, it has no cure. However, according to new research, it may be possible to slow its progression without some of the health risks ...
via Google News and Bing News